{"id":"l-folinic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Thrombocytosis"}]},"_chembl":{"chemblId":"CHEMBL1679","moleculeType":"Small molecule","molecularWeight":"473.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-folinic acid (leucovorin) is the active form of folic acid that bypasses the need for dihydrofolate reductase conversion, making it immediately available for one-carbon metabolism. It is commonly used as a rescue agent to mitigate toxicity from methotrexate and other antifolate drugs, and as an adjunct to fluorouracil-based chemotherapy to enhance efficacy by stabilizing the ternary complex of thymidylate synthase.","oneSentence":"L-folinic acid is a reduced form of folic acid that acts as a methyl donor and cofactor in one-carbon transfer reactions essential for DNA synthesis and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:07.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methotrexate toxicity rescue"},{"name":"Adjunct to fluorouracil-based chemotherapy in colorectal cancer and other malignancies"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":"Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma","enrollment":66},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":"Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":180},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT07283939","phase":"NA","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-13","conditions":"Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile","enrollment":420},{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":"Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","enrollment":314},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT02359968","phase":"PHASE2","title":"PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2015-02-26","conditions":"Esophageal Neoplasms, Gastro-esophageal Junction Cancer","enrollment":106},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":"Colorectal Cancer","enrollment":89},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT05346484","phase":"PHASE1","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2022-05-17","conditions":"Solid Tumor, Solid Carcinoma, Solid Tumor, Adult","enrollment":66},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":"Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":236},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT07415031","phase":"PHASE2","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","status":"NOT_YET_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2026-05-16","conditions":"Solid Tumors","enrollment":170},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":"Locally Advanced Pancreatic Cancer","enrollment":88},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT06219941","phase":"PHASE2","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":224},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03426904","phase":"PHASE3","title":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Colon Cancer","enrollment":708},{"nctId":"NCT07214298","phase":"PHASE1, PHASE2","title":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-01","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":35},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT07391566","phase":"PHASE1, PHASE2","title":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","status":"NOT_YET_RECRUITING","sponsor":"Luye Pharma Group Ltd.","startDate":"2026-03-31","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":99},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT07176312","phase":"PHASE2","title":"Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2026-01-16","conditions":"Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer","enrollment":80},{"nctId":"NCT07061080","phase":"PHASE2","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-12-18","conditions":"Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin","enrollment":87},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT02912559","phase":"PHASE3","title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-16","conditions":"Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome","enrollment":712},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT06381154","phase":"PHASE2","title":"Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-12-06","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":25},{"nctId":"NCT04421820","phase":"PHASE1, PHASE2","title":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","status":"RECRUITING","sponsor":"Bold Therapeutics, Inc.","startDate":"2020-08-28","conditions":"Colorectal Cancer, Pancreatic Cancer, Gastric Cancers","enrollment":220},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07363408","phase":"PHASE1","title":"Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-21","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":30},{"nctId":"NCT07359456","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06967987","phase":"PHASE2","title":"Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b","status":"WITHDRAWN","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-01-01","conditions":"Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b","enrollment":""},{"nctId":"NCT06574620","phase":"NA","title":"Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-11-28","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT05688215","phase":"PHASE1, PHASE2","title":"Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-03-07","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":56},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT03801876","phase":"PHASE3","title":"Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2019-06-26","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":300},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07337421","phase":"PHASE2","title":"Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT06821997","phase":"PHASE2","title":"NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-02-01","conditions":"Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT05504252","phase":"PHASE2","title":"METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2022-10-05","conditions":"Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma","enrollment":80},{"nctId":"NCT07277270","phase":"PHASE1","title":"A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-12-03","conditions":"Neoplasms","enrollment":84},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT01226550","phase":"PHASE1, PHASE2","title":"Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2007-06","conditions":"Peritoneal Carcinosis (PC)","enrollment":18},{"nctId":"NCT05802056","phase":"PHASE1","title":"Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-29","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":15},{"nctId":"NCT06509906","phase":"PHASE1","title":"M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-10-08","conditions":"Advanced Solid Tumor","enrollment":3}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folinic acid","LFA","ELVORIN"],"phase":"phase_3","status":"active","brandName":"L-folinic acid","genericName":"L-folinic acid","companyName":"The Christie NHS Foundation Trust","companyId":"the-christie-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-folinic acid is a reduced form of folic acid that acts as a methyl donor and cofactor in one-carbon transfer reactions essential for DNA synthesis and cell division. Used for Methotrexate toxicity rescue, Adjunct to fluorouracil-based chemotherapy in colorectal cancer and other malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}